Jubilant Pharmova (JUBLPHARMA) Fundamentals 2026 — P/E 39.3x, Revenue Analysis | SniperIQ
Jubilant Pharmova (JUBLPHARMA) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹15,664 Crore, trading at ₹993.10 on the BSE. This SniperIQ fundamentals page covers Jubilant Pharmova's valuation (P/E 39.3x, P/B 2.2x), profitability (net margin 4.8%), revenue (₹8,280 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Jubilant Pharmova's market cap?
Jubilant Pharmova (JUBLPHARMA) has a market capitalization of approximately ₹15,664 Crore, trading at ₹993.10 on the BSE. Market cap moves with the live share price.
What is Jubilant Pharmova's P/E ratio?
Jubilant Pharmova's trailing twelve-month P/E ratio is 39.3x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Jubilant Pharmova?
Jubilant Pharmova runs a net profit margin of 4.8%, a gross margin of 38.4%, and an operating margin of 15.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Jubilant Pharmova generate?
Jubilant Pharmova reported revenue of ₹8,280 Crore for fiscal year 2026, with net income of ₹399 Crore and earnings per share (EPS) of 25.15. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Jubilant Pharmova pay a dividend?
Jubilant Pharmova offers a trailing dividend yield of about 0.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Jubilant Pharmova financially healthy?
Jubilant Pharmova carries a debt-to-equity ratio of 0.51x and a current ratio of 1.62x, with a market beta of 0.51. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Jubilant Pharmova a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Jubilant Pharmova (JUBLPHARMA) the key facts are: market cap ₹15,664 Crore, P/E 39.3x, revenue ₹8,280 Crore, 52-week range 783.75-1250. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Jubilant Pharmova's full fundamentals live
Get Jubilant Pharmova's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.